Recent Finacing
Recent Raise
Topas Therapeutics develops nanoparticle Topas Particle Conjugates that induce liver‑based antigen‑specific immune tolerance to treat autoimmune diseases, allergies, and anti‑drug antibody responses; lead candidate TPM203 is in clinical development.
